Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GELS
GELS logo

GELS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.820
Open
0.820
VWAP
0.76
Vol
157.38K
Mkt Cap
13.17M
Low
0.730
Amount
119.63K
EV/EBITDA(TTM)
--
Total Shares
10.71M
EV
13.69M
EV/OCF(TTM)
--
P/S(TTM)
96.13
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
Show More

Events Timeline

(ET)
2026-02-11
09:00:00
Gelteq and Healthy Extracts Sign Strategic Partnership MOU
select
2026-01-13 (ET)
2026-01-13
09:20:00
Gelteq Oral Gel Platform Increases CBD Bioavailability by Over 22%
select
2025-12-16 (ET)
2025-12-16
09:20:00
Gelteq Announces New Partnership with Hong Kong Flag Football Program
select
2025-12-09 (ET)
2025-12-09
09:20:00
Gelteq Enters Three-Year Sales Agreement with Shenzhen Mana, Expected Revenue of $1.3 Million
select
2025-12-05 (ET)
2025-12-05
10:50:00
Gelteq Announces Preclinical Findings Demonstrating Effectiveness of Gel Platform
select
2025-11-24 (ET)
2025-11-24
08:43:18
Gelteq Reports Encouraging Preclinical Findings for Its Gel Formula
select
2025-10-23 (ET)
2025-10-23
09:09:32
Gelteq Launches Preclinical Trial for Drugs with Low Solubility
select
2025-10-09 (ET)
2025-10-09
08:15:45
Gelteq Partners with Melbourne Health for Product Development and Profit Sharing Agreement
select
2025-09-12 (ET)
2025-09-12
07:32:16
Gelteq Fuels Healthy Extracts' Product Launches in the U.S.
select
2025-07-17 (ET)
2025-07-17
08:36:25
Gelteq announces agreement with IDT Australia to secure manufacturing facility
select

News

Newsfilter
8.5
06-17Newsfilter
Gelteq Limited Reports Clinical and Commercial Milestones for H1 2026
  • Clinical Trial Progress: Gelteq has completed planning for its human clinical trial, expected to commence on July 1, 2026, advancing its pharmaceutical program toward an FDA regulatory pathway, marking a significant milestone in the biotechnology sector.
  • Animal Health Program Launch: The company has initiated a veterinary clinical trial for an antiparasitic drug candidate, with a planned FDA application targeted for later in 2026, addressing a global animal health market exceeding $78 billion, showcasing substantial commercial potential.
  • Strategic Financing Agreement: Gelteq signed a strategic debt financing agreement of up to $3.5 million with an institutional investor, with an initial funding of $1 million, aimed at supporting clinical program advancement and commercialization acceleration.
  • East Asian Market Expansion: The company successfully manufactured a commercial product for a new customer in the East Asian region, validating its capabilities in formulation, manufacturing, and delivery at commercial scale, further solidifying its position in the rapidly growing pharmaceutical market.
Newsfilter
7.5
06-12Newsfilter
Gelteq Completes Successful Veterinary Palatability Trials
  • Trial Success: Gelteq, in collaboration with Kemin, has successfully completed veterinary palatability trials, demonstrating strong canine acceptance across various flavors, validating the potential of Gelteq® technology in veterinary pharmaceuticals.
  • Technology Validation: The trials confirmed Gelteq® technology's ability to effectively mask bitter flavors while enhancing palatability, providing crucial data to support the successful development of animal therapeutics.
  • Strategic Partnership Opportunities: The results are expected to strengthen Gelteq's position in the veterinary therapeutics landscape and facilitate potential partnership discussions with pharmaceutical companies and animal health organizations.
  • Broad Market Prospects: Gelteq's CEO stated that the successful trial outcomes not only broaden the range of active pharmaceutical ingredients that can be utilized but also enhance the company's competitiveness in the evolving animal health market.
NASDAQ.COM
2.0
06-12NASDAQ.COM
Biotech Companies See Significant Stock Gains
  • Gelteq Stock Surge: Australia-based Gelteq's shares soared over 197% without specific news, as the company commenced its first clinical trial for an antiparasitic drug candidate, which is expected to drive an FDA submission and enhance market competitiveness.
  • Adial Acquires Azora: Adial Pharmaceuticals announced the acquisition of Azora Therapeutics with up to $64 million in financing, which will strengthen its pipeline for treating serious inflammatory diseases, with a Phase I clinical trial planned for 2027 expected to create new growth opportunities.
  • Precigen Commercial Momentum: Precigen's PAPZIMEOS sales reached $21.6 million in Q1 2026, a significant increase from $3.4 million in Q4 2025, indicating strong commercialization momentum in the U.S. market, with expectations for further market share expansion.
  • Eloxx Nasdaq Uplisting: Eloxx Pharmaceuticals' stock rose over 14% following its uplisting to Nasdaq, with plans to initiate a Phase 2b clinical trial for its lead drug Exaluren targeting Alport syndrome in Q3 2026, which is expected to provide new growth opportunities for the company.
Newsfilter
4.5
06-04Newsfilter
Gelteq Establishes Center of Excellence in Guangdong, China
  • Regional Innovation Hub: Gelteq's establishment of a Center of Excellence in Guangdong, China, will serve as a strategic regional hub, enhancing integration with one of the world's fastest-growing pharmaceutical and biotechnology ecosystems, thereby strengthening the company's globally integrated development platform.
  • Accelerated Product Development: The center is expected to support accelerated product development and commercialization timelines, expand formulation, testing, and product optimization capabilities, and increase the capacity to advance multiple development programs simultaneously, significantly improving operational efficiency.
  • Market Participation Opportunities: According to PharmCube, cross-border out-licensing transactions originating from China are estimated at nearly $60 billion in deal value during Q1 2026, positioning Gelteq to participate more closely in the rapidly expanding biotechnology and pharmaceutical innovation market and seize lucrative commercial opportunities.
  • Strategic Development Goals: CEO Nathan Givoni stated that the establishment of this center represents a significant milestone in expanding Gelteq's global development and commercial capabilities, aiming to drive long-term product pipeline development through enhanced operational scalability and accelerated product development.
Newsfilter
9.0
05-20Newsfilter
Gelteq Initiates First Clinical Trial for Veterinary Drug Candidate
  • Clinical Trial Launch: Gelteq has announced the initiation of its first clinical trial for an antiparasitic drug candidate, marking a significant milestone as the company expands into the veterinary pharmaceutical sector, with plans to support an FDA application later in 2026.
  • Technology Application Expansion: This clinical trial aims to validate the safety and efficacy of Gelteq® technology in the animal health sector, further solidifying its application potential in the veterinary market and positioning the company to capture opportunities in a rapidly growing market.
  • Market Opportunities: The global animal health market is projected to exceed USD $78 billion by 2026, with antiparasitic treatments representing a significant segment driven by increasing pet ownership and ongoing demand for parasite prevention, which Gelteq plans to leverage for expanding its commercial prospects.
  • Sufficient Funding: Gelteq's recent financing provides the company with adequate capital to execute its dual-track strategy of advancing long-term pharmaceutical projects while also driving near-term revenue growth through its nutraceutical portfolio, enhancing overall financial health.
seekingalpha
8.5
05-12seekingalpha
Gelteq Secures $3.5 Million Debt Financing for Growth
  • Financing Amount: Gelteq Limited announced it has secured up to $3.5 million in debt financing, which includes $1 million at closing and an additional $2.5 million subject to shareholder approval expected in June.
  • Clinical Trial Expansion: The proceeds will be utilized to expand clinical trial programs, support regulatory pathways for pharmaceutical products, and accelerate the commercialization of its nutraceutical products, thereby enhancing the company's competitive position in the market.
  • No Repayment Pressure: The financing agreement stipulates no repayments for at least six months from closing, providing the company ample time to implement its commercialization strategy and drive revenue growth.
  • Strategic Implications: This financing not only strengthens Gelteq's R&D capabilities but also positions the company favorably in the rapidly growing nutraceutical market, further propelling long-term growth.

Valuation Metrics

The current forward P/E ratio for Gelteq Ltd (GELS.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Gelteq Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding GELS

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Gelteq Ltd (GELS) stock price today?

The current price of GELS is 0.7303 USD — it has decreased -16.08

What is Gelteq Ltd (GELS)'s business?

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

What is the price predicton of GELS Stock?

Wall Street analysts forecast GELS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GELS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Gelteq Ltd (GELS)'s revenue for the last quarter?

Gelteq Ltd revenue for the last quarter amounts to 0.00 USD, decreased

What is Gelteq Ltd (GELS)'s earnings per share (EPS) for the last quarter?

Gelteq Ltd. EPS for the last quarter amounts to -0.12 USD, increased 20.00

How many employees does Gelteq Ltd (GELS). have?

Gelteq Ltd (GELS) has 7 emplpoyees as of June 24 2026.

What is Gelteq Ltd (GELS) market cap?

Today GELS has the market capitalization of 13.17M USD.